Colorectal cancer (CRC) is one of the most common and deadly cancers. One of the major problems in the management of CRC patients is tumor recidivism. This recurrence can be explained in particular by the presence of cancer stem cells (CSCs) resistant to conventional therapies. This research program focuses on identifying effective treatment for colorectal cancers for both proliferative tumour cells and cancer stem cells in CRC. It will identify the specific characteristics of CRC patients who may benefit from this new treatment. The CCS project is a collaborative R&D project involving: — an academic partner: INSERM through the CBS (Centre for Structural Biochemistry) and IGF (Institute of Functional Genomics) laboratories, of which the CNRS, INSERM, and the UNIVERSITY DE MONTPELLIER are co-tutelles and — an industrial partner: AGV DISCOVERY (SME of Occitanie — Dpt 34 Montpellier), a pharmaceutical company created in March 2013 specialising in the design of targeted therapies in the field of oncology.